Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-30 | Abliva | Ändring av antal aktier och röster i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-30 | Abliva | Amended number of shares and votes in Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Abliva | Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Abliva | Abliva beslutar om en riktad emission av aktier till garanter i samband med den genomförda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Abliva | Abliva AB publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Abliva | Abliva AB Publishes 2023 Annual Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Abliva | Kallelse till årsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Abliva | Notice of Annual General Meeting of Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-19 | Abliva | Abliva publishes rights issue outcome | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-19 | Abliva | Abliva offentliggör utfall i företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-08 | Abliva | BioStock: Abliva vill bli en nyckelspelare inom mitokondriell medicin | Pressreleaser | Visa Stäng |
|
||||
2024-04-08 | Abliva | BioStock: Abliva's mission to become mitochondrial medicine powerhouse | Pressreleaser | Visa Stäng |
|
||||
2024-03-27 | Abliva | Abliva offentliggör prospekt med anledning av företrädesemission som till 100 procent omfattas av tecknings- och garantiåtaganden och upptagande till handel av nyemitterade aktier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Abliva | Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Abliva | Resolutions at the Extraordinary General Meeting in Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today 26 March 2024 held an Extraordinary General Meeting. A summary of the resolutions follows. The resolutions were passed unanimously. Amendment of the Articles of Association §4 in the Articles of Association is to be amended from: §5 in the Articles of Association is to be amended from: Approval of the Board of Directors’ resolution on a preferential rights issue The record date for determining which shareholders who are entitled to subscribe for shares with preferential right shall be 28 March 2024. Subscription of shares with subscription rights shall be made through payment in cash during the period from and including 3 April 2024 up to and including 17 April 2024. The Board of Directors shall have the right to extend the subscription and payment period. Subscription of shares without subscription rights shall be made during the same period as subscription of shares with subscription rights, meaning during the period from and including 3 April 2024 up to and including 17 April 2024. The Board of Directors shall have the right to extend the subscription and payment period. Approval of the Board of Directors’ resolution on a directed issue of convertible bonds Entitled to subscribe for the convertible bonds in the issue shall be institutional and professional investors. The Board of Directors believes that it is advantageous for the Company and for the Company’s owners to capitalize on the flexibility to raise capital on favorable terms and in a timely and cost-effective manner from institutional and professional investors. The issue of convertibles, which is made with deviation from the shareholders’ pre-emptive rights, will promote value creation for all shareholders of the Company. The Board of Director’s overall assessment is therefore that there are good reasons to deviate from the shareholders’ preferential right and carry out the directed issue. The nominal amount of the convertible bonds shall be SEK one (1) or multiples thereof. The subscription price shall be equal to the nominal amount of the convertible bonds. The subscription price and the conversion rate have been determined based on the Company’s shares listed market price and the convertible loan’s value after negotiations with the subscribers and following the recommendations from an independent financial advisor. Holders of the convertible bonds shall convert all of the loan amount, according to the Convertible Bond 2024 into shares in the Company in accordance with the Terms and Conditions for the Convertible Bond within five banking days from the time at which the Company announces the interim data from the KL 1333 Phase II-study if it results in a positive, i.e. non futile, outcome at a conversion price of SEK 0.000000380952380952381. One (1) convertible can be converted into 2,625,000 shares. In connection with the conversion, holders of the convertibles shall pay an additional amount of SEK 0.049999619047619 per share created through conversion to the Company to cover the difference between the conversion rate and the quota share value. In addition, holders of the convertibles shall, in connection with the conversion, pay an additional amount to the Company of SEK 0.11 per share created through conversion. These two additional payments do not constitute a part of the Convertible Bond 2024. Payment of the convertible loan shall be due on 30 September 2024 provided conversion has not been made before. Given that the conversion price for the Convertible Bond 2024, together with the two additional payments in connection with the conversion, shall correspond to the subscription price of SEK 0.16 in the rights issue that was resolved by the Board of Directors and approved by the extraordinary general meeting, at the same time as the Convertible Bond 2024 (the “ Rights Issue “), a recalculation of the conversion price according to the Terms and Conditions of the Convertible Bond, as a result of the Rights Issue will not be carried out. In case of full conversion of the bonds on the last day for conversion, the issue entails an increase of the share capital of not more than SEK 13,125,000. Authorization for the Board of Directors to decide on new issue of shares, warrants and/or convertibles |
||||
2024-03-26 | Abliva | Beslut vid extra bolagsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Abliva | BioStock: Abliva's CEO comments on the proposed capital raise | Pressreleaser | Visa Stäng |
|
||||
2024-02-29 | Abliva | BioStock: Ablivas vd kommenterar den föreslagna kapitalanskaffningen | Pressreleaser | Visa Stäng |
|
||||
2024-02-27 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - Interimdata i sommar | Pressreleaser | Visa Stäng |
|
||||
2024-02-23 | Abliva | Abliva AB Year-End Report January – December 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Abliva | Abliva AB Bokslutskommuniké januari – december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Kallelse till extra bolagsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Notice of Extraordinary General Meeting of Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Styrelsen för Abliva beslutar om en fullt garanterad företrädesemission om 46 MSEK och en riktad emission av konvertibler om 42 MSEK för att förbereda slutfasen av FALCON-studien med KL1333 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Abliva | BioStock: Abliva reaches enrollment goal | Pressreleaser | Visa Stäng |
|
||||
2023-12-21 | Abliva | BioStock: Abliva når mål för patientinkludering | Pressreleaser | Visa Stäng |
|
||||
2023-12-20 | Abliva | Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Abliva | Abliva når mål för patientinkludering i Steg 1 av FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-15 | Abliva | BioStock: Ablivas vd: "Orphan drug designation is great validation" | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Abliva | BioStock: Abliva's CEO: "Orphan drug designation is great validation" | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - Huvudkonkurrent misslyckas | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - 4 minutes by Penser | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Abliva | Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-14 | Abliva | Abliva erhåller särläkemedelsklassificering från EU-kommissionen för sin läkemedelskandidat NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-20 | Penser Future | Penser Future: Luft under vingarna - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Delårsrapport januari – september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Interim Report January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva tecknar globalt licensavtal för NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva signs global license deal for NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-15 | Penser Future | Penser Future: Licensierar ut NeuroSTAT - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva och Owl Therapeutics ingår licens- och samarbetsavtal för NeuroSTAT® vid traumatisk hjärnskada | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Abliva | Abliva presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Ablivas VP of Clinical Operations om uppnått screening-mål | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Abliva's VP of Clinical Operations on the screening achievement | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Abliva | Abliva Achieves Important Milestone in the Ongoing FALCON Study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Abliva | Abliva når viktig milstolpe i den pågående FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva ökar medvetenheten om mitkondriella sjukdomar | Pressreleaser | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva increases awareness of mitochondrial diseases | Pressreleaser | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva to Participate in World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva uppmärksammar World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva erhåller FDA Fast Track-status | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva receives FDA Fast Track designation | Pressreleaser | Visa Stäng |
|
||||
2023-09-04 | Abliva | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-04 | Abliva | Ablivas huvudkandidat KL1333 får Fast Track-status från FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Penser Future | Penser Future: Patientrekrytering i fokus - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-08-18 | Abliva | Abliva AB Delårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-18 | Abliva | Abliva AB Interim Report January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presents at UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presenterar på UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva announces first patient dosed in the FALCON study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva meddelar att första patienten doserats i FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Abliva's presence is felt at Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Ablivas CMO om presentation på Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presents scientific data at international conference on mitochondrial medicine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presenterar vetenskapliga data vid internationell konferens inom mitokondriell medicin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Interview with Abliva - Erik Penser Bank - May 24th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Tidsplan för FALCON-studien intakt - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Delårsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Interim Report January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|